Cilostazol Use in Clinical Practice for Peripheral Arterial Disease
Primary Indication and Mechanism of Action
- The American College of Cardiology recommends cilostazol as a phosphodiesterase type III inhibitor that increases cyclic adenosine monophosphate (cAMP), providing vasodilator and platelet inhibitory properties, with a recommended dose of 100 mg orally twice daily 1
- Cilostazol improves maximal walking distance by 40% to 60% compared with placebo after 12 to 24 weeks of therapy in patients with intermittent claudication, according to the American College of Cardiology 2, 3
Dosing and Administration
- The American College of Cardiology suggests assessing patient tolerance at 2-4 weeks and evaluating benefit within 3-6 months to determine if long-term therapy will be beneficial 3
- Approximately 20% of patients discontinue cilostazol within 3 months due to side effects, as reported by the American College of Cardiology 3
Clinical Benefits Beyond Symptom Relief
- Cilostazol modestly increases ankle-brachial index (ABI), though this hemodynamic effect does not fully account for the improvement in claudication symptoms, according to the American College of Cardiology 2, 4
- The American College of Cardiology suggests that cilostazol may reduce restenosis after endovascular therapy for femoropopliteal disease 3, 5
Important Contraindications and Safety Considerations
- The American College of Cardiology states that cilostazol is absolutely contraindicated in patients with heart failure of any severity 3, 6
- The FDA has mandated a black box warning against use in heart failure patients due to concerns about increased mortality risk associated with phosphodiesterase III inhibitors in this population, as reported by the American College of Cardiology 1, 6
Comparative Efficacy
- The American College of Cardiology recommends cilostazol as first-line pharmacotherapy for claudication, with pentoxifylline considered only as a second-line alternative with marginal clinical effectiveness 7, 8
- Cilostazol is superior to pentoxifylline for improving walking distance in patients with intermittent claudication, according to the American College of Cardiology 7